JP2018534311A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534311A5 JP2018534311A5 JP2018525700A JP2018525700A JP2018534311A5 JP 2018534311 A5 JP2018534311 A5 JP 2018534311A5 JP 2018525700 A JP2018525700 A JP 2018525700A JP 2018525700 A JP2018525700 A JP 2018525700A JP 2018534311 A5 JP2018534311 A5 JP 2018534311A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- raf
- inhibitor
- administered
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 38
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 claims 28
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 claims 28
- 239000003112 inhibitor Substances 0.000 claims 23
- 201000001441 melanoma Diseases 0.000 claims 15
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 10
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 10
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 10
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 10
- 229940124647 MEK inhibitor Drugs 0.000 claims 7
- 229960002271 cobimetinib Drugs 0.000 claims 7
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical group OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims 7
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 7
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical group CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 5
- 229960003862 vemurafenib Drugs 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 229960003852 atezolizumab Drugs 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- -1 (S)-[3,4-difluoro-2- (2-fluoro-4-iodophenylamino) phenyl] [3-hydroxy-3- (piperidin-2-yl) azetidin-1-yl ] Chemical group 0.000 claims 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 208000021039 metastatic melanoma Diseases 0.000 claims 2
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000005723 MEK inhibition Effects 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical group CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257645P | 2015-11-19 | 2015-11-19 | |
| US62/257,645 | 2015-11-19 | ||
| PCT/US2016/062859 WO2017087851A1 (en) | 2015-11-19 | 2016-11-18 | Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018534311A JP2018534311A (ja) | 2018-11-22 |
| JP2018534311A5 true JP2018534311A5 (https=) | 2019-12-26 |
| JP6952691B2 JP6952691B2 (ja) | 2021-10-20 |
Family
ID=57485956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018525700A Active JP6952691B2 (ja) | 2015-11-19 | 2016-11-18 | Ｂ−ｒａｆ阻害剤及び免疫チェックポイント阻害剤を使用してがんを治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20180256552A1 (https=) |
| EP (1) | EP3377107B1 (https=) |
| JP (1) | JP6952691B2 (https=) |
| KR (1) | KR102702851B1 (https=) |
| CN (2) | CN108136022A (https=) |
| AU (1) | AU2016355320B2 (https=) |
| ES (1) | ES2824120T3 (https=) |
| HK (1) | HK1256367A1 (https=) |
| IL (1) | IL259055B (https=) |
| MX (1) | MX377351B (https=) |
| PL (1) | PL3377107T3 (https=) |
| WO (1) | WO2017087851A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| KR20180097615A (ko) | 2016-01-08 | 2018-08-31 | 에프. 호프만-라 로슈 아게 | Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| EP3493844A4 (en) | 2016-05-20 | 2021-03-24 | Harpoon Therapeutics Inc. | SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| CN110914302A (zh) * | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| JP2022504905A (ja) * | 2018-10-16 | 2022-01-13 | ノバルティス アーゲー | 標的化療法に対する応答を予測するためのバイオマーカーとしての単独の又は免疫マーカーと組み合わせた腫瘍突然変異負荷 |
| WO2021016228A1 (en) * | 2019-07-22 | 2021-01-28 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Combination therapy for treating ras-mutant cancers |
| WO2022131667A1 (ko) * | 2020-12-18 | 2022-06-23 | 경희대학교 산학협력단 | Oligodendrocyte transcription factor 2 억제제를 유효성분으로 포함하는 흑색종 치료 효과 증진용 약학적 조성물 |
| KR20230167097A (ko) * | 2021-04-09 | 2023-12-07 | 제넨테크, 인크. | Raf 억제제와 pd-1 축 억제제를 사용한 병용 요법 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| UA95244C2 (ru) | 2005-06-22 | 2011-07-25 | Плексикон, Инк. | Соединения и способ модулирования активности киназ, и показания для их применения |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| SI1934174T1 (sl) | 2005-10-07 | 2011-08-31 | Exelixis Inc | Inhibitorji MEK in postopki za njihovo uporabo |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| KR20100122505A (ko) | 2008-02-29 | 2010-11-22 | 어레이 바이오파마 인크. | Ｒａｆ 저해물질 화합물 및 이들의 이용 방법 |
| JP2011513331A (ja) | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤 |
| CA2716947A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
| JP2011513332A (ja) | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| KR20190057421A (ko) * | 2012-08-17 | 2019-05-28 | 에프. 호프만-라 로슈 아게 | 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법 |
| ES2822665T3 (es) * | 2013-05-31 | 2021-05-04 | Merck Sharp & Dohme | Terapias de combinación para el cáncer |
| TN2015000444A1 (en) * | 2013-06-03 | 2017-04-06 | Novartis Ag | Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor |
-
2016
- 2016-11-18 WO PCT/US2016/062859 patent/WO2017087851A1/en not_active Ceased
- 2016-11-18 JP JP2018525700A patent/JP6952691B2/ja active Active
- 2016-11-18 PL PL16806416T patent/PL3377107T3/pl unknown
- 2016-11-18 EP EP16806416.0A patent/EP3377107B1/en active Active
- 2016-11-18 AU AU2016355320A patent/AU2016355320B2/en active Active
- 2016-11-18 MX MX2018006152A patent/MX377351B/es active IP Right Grant
- 2016-11-18 CN CN201680051333.4A patent/CN108136022A/zh active Pending
- 2016-11-18 ES ES16806416T patent/ES2824120T3/es active Active
- 2016-11-18 HK HK18115456.5A patent/HK1256367A1/zh unknown
- 2016-11-18 KR KR1020187016785A patent/KR102702851B1/ko active Active
- 2016-11-18 CN CN202510876831.3A patent/CN121154828A/zh active Pending
-
2018
- 2018-04-30 IL IL259055A patent/IL259055B/en unknown
- 2018-05-18 US US15/984,067 patent/US20180256552A1/en not_active Abandoned
-
2019
- 2019-11-13 US US16/683,082 patent/US20200155520A1/en not_active Abandoned
-
2023
- 2023-12-18 US US18/544,236 patent/US20240115555A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534311A5 (https=) | ||
| JP7194022B2 (ja) | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 | |
| CN102089007B (zh) | (a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品 | |
| JP2017529382A5 (https=) | ||
| JP2017502017A5 (https=) | ||
| JP2017522307A5 (https=) | ||
| JP2014509657A5 (https=) | ||
| JP2013539767A5 (https=) | ||
| JP2019511526A5 (https=) | ||
| RU2017102319A (ru) | Прерывистое введение ингибитора mdm2 | |
| JP2014532648A5 (https=) | ||
| JP2018507243A5 (https=) | ||
| JP2018519324A5 (https=) | ||
| Pardanani et al. | A phase I/II study of CYT387, an oral JAK-1/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms | |
| WO2018060463A3 (en) | Treatment of prostate cancer | |
| JP2018530578A5 (https=) | ||
| JP2017502016A5 (https=) | ||
| JP2021509395A5 (https=) | ||
| US20130131069A1 (en) | Method for treatment of solid malignancies including advanced or metastatic solid malignancies | |
| CN104039148A (zh) | 组合als疗法 | |
| Gibofsky et al. | Lower-dose diclofenac submicron particle capsules provide early and sustained acute patient pain relief in a phase 3 study | |
| Dunne et al. | A phase 1 study to assess the pharmacokinetics of sulopenem etzadroxil (PF-03709270) | |
| JP2016505050A5 (https=) | ||
| JP2021505669A5 (https=) | ||
| WO2006060731A3 (en) | Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1 |